No Prescription |
 |
 | ||
|
Cardinol LA Inderal |
|
| ||
No Prescription » Prescription Drugs 3 » Cardinol LA Inderal CARDINOL LA capsules contain the active ingredient propranolol hydrochloride which belongs to a group of medicines called beta-blockers. These medicines work by changing the body's response to some nerve impulses especially in the heart.CARDINOL LA is used to lower blood pressure help in the prevention of chest pain (angina) and for the long-term prevention of future heart attacks. Buy Cardinol LA Inderal and other Prescription Drugs 3 products online at Medstore. 5175
About Cardinol LA Inderal: Product Type: Prescription Drugs 3 Cardinol LA ( Inderal Dideral Generic Propranolol ) Cardinol LA (Inderal Dideral Generic Propranolol) Inderal Dideral Generic Propranolol 160mg 100 Tablets Inderal Dideral Generic Propranolol Cardinol LA
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
